Legalize59765 laws
59765 laws
- § 8432. Recruit basic training: privacy
- § 5828. Funding for OPIC programs
- § 844. Art. 44. Former jeopardy
- § 5841. Authorization for establishment of Democracy Corps
- § 8451a. Superintendent
- § 360bbb–1. Dispute resolution
- § 348. Food additives
- § 349. Bottled drinking water standards; publication in Federal Register
- § 350. Vitamins and minerals
- § 350a. Infant formulas
- § 350a–1. Protecting infants and improving formula supply
- § 350b. New dietary ingredients
- § 350c. Maintenance and inspection of records
- § 350d. Registration of food facilities
- § 350e. Sanitary transportation practices
- § 350f. Reportable food registry
- § 360fff–7. Report
- § 350g. Hazard analysis and risk-based preventive controls
- § 350h. Standards for produce safety
- § 350i. Protection against intentional adulteration
- § 350j. Targeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report
- § 350k. Laboratory accreditation for analyses of foods
- § 350l. Mandatory recall authority
- § 350l–1. Annual report to Congress
- § 350m. Requirements for critical food
- § 351. Adulterated drugs and devices
- § 352. Misbranded drugs and devices
- § 356h. Competitive generic therapies
- § 8460. Midshipmen: clothing and equipment; uniform allowance
- § 353. Exemptions and consideration for certain drugs, devices, and biological products
- § 353a. Pharmacy compounding
- § 353a–1. Enhanced communication
- § 353b. Outsourcing facilities
- § 353c. Prereview of television advertisements
- § 353d. Process to update labeling for certain generic drugs
- § 354. Veterinary feed directive drugs
- § 355. New drugs
- § 355a. Pediatric studies of drugs
- § 355b. Adverse-event reporting
- § 8465. Failure to report violation: dismissal
- § 355c. Research into pediatric uses for drugs and biological products
- § 355c–1. Report
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355e. Pharmaceutical security
- § 355f. Extension of exclusivity period for new qualified infectious disease products
- § 355g. Utilizing real world evidence
- § 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application
- § 355–1. Risk evaluation and mitigation strategies
- § 355–2. Actions for delays of generic drugs and biosimilar biological products
- § 285e–5. Research relevant to appropriate services for individuals with Alzheimer’s disease and related dementias and their families